Zobrazeno 1 - 10 of 185 pro vyhledávání: '"Timothy J Vreeland"'
1
Akademický článek
Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial
Autor: Spencer G. Van Decar, Elizabeth L. Carpenter, Alexandra M. Adams, Robert C. Chick, Guy T. Clifton, Alex Stojadinovic, Timothy J. Vreeland, Franklin A. Valdera, Ankur Tiwari, Anne E. O'Shea, Patrick M. McCarthy, Diane F. Hale, Phillip M Kemp Bohan, Annelies T. Hickerson, Jessica L. Cindass, John Hyngstrom, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Montaser Shaheen, Xianzhong Yu, Thomas Wagner, Mark B. Faries, George E. Peoples
Publikováno v: Cancer Treatment and Research Communications, Vol 41, Iss , Pp 100843- (2024)
Background: The autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is produced from dendritic cells (DC) loaded ex vivo with autologous tumor lysate (TL). TLPLDC has been shown to decrease recurrence in resected Stage III/IV me
Externí odkaz: https://doaj.org/article/26a0b32110ad4f309bb06e391026d393
Zobrazit plný text záznamu
2
Akademický článek
Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials
Autor: Patrick M. McCarthy, Franklin A. Valdera, Todd R. Smolinsky, Alexandra M. Adams, Anne E. O’Shea, Katryna K. Thomas, Spencer Van Decar, Elizabeth L. Carpenter, Ankur Tiwari, John W. Myers, Diane F. Hale, Timothy J. Vreeland, George E. Peoples, Alex Stojadinovic, Guy T. Clifton
Publikováno v: Frontiers in Immunology, Vol 14 (2023)
Checkpoint inhibitors have invigorated cancer immunotherapy research, including cancer vaccination. Classic early phase trial design and endpoints used in developing chemotherapy are not suited for evaluating all forms of cancer treatment. Peripheral
Externí odkaz: https://doaj.org/article/bc7c7eccb0dc43ea82221b1220d847ed
Zobrazit plný text záznamu
3
Akademický článek
Multi‐institutional, prospective, randomized, double‐blind, placebo‐controlled phase IIb trial of the tumor lysate, particle‐loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high‐risk melanoma patients: A subgroup analysis
Autor: Robert C. Chick, Mark B. Faries, Diane F. Hale, Phillip M Kemp Bohan, Annelies T. Hickerson, Timothy J. Vreeland, John W. Myers III, Jessica L. Cindass, Tommy A. Brown II, John Hyngstrom, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Montaser Shaheen, Guy T. Clifton, Hyohyun Park, Amanda J. Sloan, Thomas Wagner, George E. Peoples
Publikováno v: Cancer Medicine, Vol 10, Iss 13, Pp 4302-4311 (2021)
Abstract Background Checkpoint inhibitors (CPI) in combination with cell‐based vaccines may produce synergistic antitumor immunity. The primary analysis of the randomized and blinded phase IIb trial in resected stage III/IV melanoma demonstrated TL
Externí odkaz: https://doaj.org/article/a6753864134f45a6a3f365c4aa4d21de
Zobrazit plný text záznamu
4
Akademický článek
Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients
Autor: Tommy A. Brown, Kevin Byrd, Timothy J. Vreeland, Guy T. Clifton, Doreen O. Jackson, Diane F. Hale, Garth S. Herbert, John W. Myers, Julia M. Greene, John S. Berry, Jonathan Martin, John C. Elkas, Thomas P. Conrads, Kathleen M. Darcy, Chad A. Hamilton, George L. Maxwel, George E. Peoples
Publikováno v: Cancer Medicine, Vol 8, Iss 10, Pp 4678-4687 (2019)
Abstract Background E39, an HLA‐A2‐restricted, immunogenic peptide derived from the folate‐binding protein (FBP), is overexpressed in multiple malignancies. We conducted a phase I/IIa trial of the E39 + GM‐CSF vaccine with booster inoculation
Externí odkaz: https://doaj.org/article/f15fd5bad15e44cabf5f4b8e235a3c91
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje